Publications by authors named "Marcin Kedzior"
Article Synopsis
- Daratumumab (Dara) is the first monoclonal antibody used to treat multiple myeloma (MM), showing effectiveness but also an increased risk of infectious complications (ICs) during treatment.
- A study reviewed data from 139 MM patients treated with Dara from July 2019 to March 2024, finding that 39.6% experienced ICs, primarily pneumonia and upper respiratory infections, with some patients facing severe complications requiring hospitalization.
- Predictive models using various algorithms were developed to identify factors influencing severe ICs, highlighting the importance of hemoglobin levels and performance status in determining patient risk during treatment.
Introduction: Autologous hematopoietic stem cell transplantation (auto- HSCT) preceded by high-dose chemotherapy is a mainstay in relapsed/refractory lymphoma. The study aimed to compare the efficacy and adverse event profile between BEAM and Benda-EAM (BeEAM) regimens and to evaluate prognostic factors for survival in lymphoma patients undergoing auto-HSCT.
Material And Methods: We present a single-center retrospective analysis of 82 lymphoma patients (median age 52; IQR 38.